Welcome to our dedicated page for Sanara Medtech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanara MedTech Inc. (SMTI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sanara’s recent filings include multiple Form 8-K current reports that furnish press releases and investor materials related to financial results, strategic decisions and leadership changes.
Form 8-K filings referenced by the company cover several key areas. One set of 8-Ks furnishes press releases announcing quarterly financial results, including discussions of net revenue, segment performance and the classification of Tissue Health Plus (THP) as discontinued operations following a strategic realignment. Another 8-K furnishes a press release detailing the decision to discontinue THP operations and reallocate resources to the core surgical business. Additional 8-K disclosures address executive leadership changes, such as the appointment of a new President and Chief Executive Officer and the designation of a principal accounting officer, along with a summary of the CEO’s employment agreement.
Sanara has also filed an 8-K furnishing an investor presentation under Regulation FD, which it intends to use in meetings with investors and analysts. This presentation, provided as an exhibit, summarizes the company’s priorities and strategy for a future fiscal year and is meant to be considered alongside its other SEC filings and public announcements.
On Stock Titan, these filings can be viewed in sequence to understand how Sanara reports its financial condition, strategic realignments, executive transitions and investor communications. The platform surfaces real-time updates from EDGAR and pairs them with AI-powered summaries that explain the context and key points of each filing, helping readers quickly interpret Form 8-K disclosures, attached exhibits and other regulatory documents related to SMTI.
Sanara MedTech Inc. reported a routine equity compensation event for its Chief Executive Officer, Yon Seth D. On the vesting of 2,082 shares of previously granted restricted stock, the company withheld 596 shares of common stock to cover tax obligations, using a per-share value of $18.87. The footnote clarifies that no shares were issued or sold on the market in this transaction. Following the tax-withholding disposition, the CEO directly owns 87,968 shares of Sanara MedTech common stock.
Sanara MedTech Inc. Chief Executive Officer Seth D. Yon filed an amended insider report updating a prior tax-related share withholding. The company withheld 414 shares of common stock at $20.44 per share to cover taxes on the vesting of 1,446 restricted shares, correcting an earlier filing that had shown 491 shares withheld. This was a tax-withholding disposition only, and the filing states that no shares were issued or sold in the transaction. After this adjustment, Yon directly holds 88,564 shares of Sanara MedTech common stock.
Sanara MedTech Inc.’s Chief Executive Officer, Yon Seth D, reported a Form 4 showing a tax-withholding disposition of 491 shares of common stock on March 1, 2026. These shares were withheld by the company to cover tax obligations from the annual vesting of 1,446 previously granted restricted shares, at a reference price of $20.44 per share. The filing notes that no shares were issued or sold in this transaction, and the CEO’s directly held stake after the withholding was 88,487 common shares.
Sanara MedTech Inc. filed a current report to furnish an investor presentation it plans to use with investors and analysts, including at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The presentation, attached as Exhibit 99.1, outlines the company’s priorities, strategy and anticipated revenue for fiscal 2026.
The company notes this information is being furnished under Regulation FD, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other Securities Act or Exchange Act filings.
Sanara MedTech Inc. director and Chief Executive Officer Yon Seth D reported a tax-related share withholding tied to restricted stock vesting. The company withheld 873 shares of common stock to cover tax obligations when 3,049 previously granted restricted shares vested, and no shares were issued or sold in the market. After this withholding, Yon Seth D directly owns 88,978 shares of Sanara MedTech common stock.
Sanara MedTech Inc.’s Chief Operating Officer Jacob A. Waldrop reported an automatic share withholding related to equity compensation. On the transaction date, 714 shares of common stock were withheld by the company at $19.90 per share to cover tax obligations from the annual vesting of 2,930 restricted stock shares previously granted to him. The filing states that no shares were issued or sold in the open market as part of this tax-withholding disposition, and Waldrop’s direct holdings after the transaction total 10,799 common shares.
Sanara MedTech Inc. Chief Financial Officer Elizabeth B. Taylor reported a tax-related share disposition tied to vesting of restricted stock. On the vesting of 1,794 restricted shares, the company withheld 437 shares of common stock at $19.90 per share to cover tax withholding obligations.
The footnote clarifies that no shares were issued or sold on the open market; the shares were retained by the company to satisfy taxes. After this withholding transaction, Taylor directly owns 4,945 shares of Sanara MedTech common stock.
Sanara MedTech Inc. Controller Ashley M. Mackey reported a tax-related share disposition. The company withheld 149 shares of common stock at $19.90 per share to cover tax obligations tied to the vesting of 502 restricted shares. After this withholding, Mackey directly owns 2,263 common shares.
Baird Trust Company, Baird Financial Corporation, and Baird Financial Group, Inc. report significant ownership of Sanara MedTech Inc. common stock. The filing shows beneficial ownership of 760,293 shares, representing 8.5% of the company’s common stock, calculated against 8,901,903 shares outstanding as of March 18, 2025.
The shares are held in client accounts over which Baird Trust has investment discretion or voting authority, and the reporting persons state they are holding the securities in the ordinary course of business, not to change or influence control of Sanara MedTech.
Sanara MedTech Inc. filed a current report to let investors know it has released a press release with certain preliminary financial results for the fourth quarter and full year 2025. The company states that this press release, dated January 23, 2026, is provided as an exhibit to the report and is incorporated by reference.
The company also clarifies that the information in this report, including the press release, is being furnished rather than filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities filings unless specifically referenced.